Rationale: Cell proliferation and cell cycle control mechanisms are thought to play central roles in the pathogenesis of atherosclerosis. The transcription factor Zinc finger protein 148 (Zfp148) was shown recently to maintain cell proliferation under oxidative conditions by suppressing p53, a checkpoint protein that arrests proliferation in response to various stressors. It is established that inactivation of p53 accelerates atherosclerosis, but whether increased p53 activation confers protection against the disease remains to be determined.
A therosclerosis is a chronic inflammatory disease driven by hyperlipidemia. Consequently, drug therapies in clinical use or in late-stage clinical trials target inflammation or lipid metabolism. However, despite the success of cholesterollowering drugs, disease progression is seen in many patients, emphasizing the need for alternative therapies that target other pathways. 1 Recent findings implicate cell cycle control mechanisms in the pathogenesis of atherosclerosis. Genetic risk variants for atherosclerosis cluster at chromosome 9p21 in proximity of the cyclin-dependent kinase inhibitor 2a (Cdkn2a) gene, which encodes p16 ink4a and p14 ARF . [2] [3] [4] Studies in mice confirm that inactivation of Cdkn2a in bone marrow-derived cells accelerates atherosclerosis in the low-density lipoprotein receptor (Ldlr) -/model, and that selective targeting of p19 ARF , the mouse homolog of p14 ARF , accelerates atherosclerosis in the apolipoprotein E (Apoe) -/model. 5, 6 The main function of p19 ARF is to activate p53, a checkpoint protein that induces cell cycle arrest or apoptosis in response to various stressors, suggesting that p53 protects against atherosclerosis. Consistent with this argument, knockout of p53 in the Apoe -/model, 7, 8 or knockout of p53 in bone marrow-derived cells in the Apoe -/-, Apoe*3-Leiden, or Ldlr -/models, [8] [9] [10] leads to increased levels of atherosclerosis. However, whether increased p53 activation would reduce the levels of atherosclerosis remains to be determined.
Zinc finger protein 148 (Zfp148, ZBP-89, BFCOL, BERF1, htβ) is a Krüppel type transcription factor that binds to GCrich DNA sequences and thereby activates or represses transcription of target genes. [11] [12] [13] [14] [15] [16] [17] [18] Zfp148 interacts physically with p53 19 and the significance of this interaction was recently discovered. 19, 20 Mice lacking both copies of Zfp148 exhibit respiratory distress because of arrested cell proliferation in the prenatal lung and half of the mice die shortly after birth. Deletion of 1 or 2 copies of Trp53 (the gene encoding p53) restored cell proliferation and rescued Zfp148-deficient mice from neonatal lethality. In cultured cells, Zfp148 deficiency lowered the threshold for p53 activation under oxidative conditions. Mice lacking 1 copy of Zfp148 have no apparent phenotypes. The role of Zfp148 and its impact on p53 activity in the pathogenesis of atherosclerosis are unknown.
In this study, we hypothesized that Zfp148 deficiency would increase p53 activation and reduce atherosclerosis development in mice. To test this we bred Zfp148 gt/+ mice with Apoe -/mice and studied atherosclerosis development in mice fed high-fat or normal diets.
Methods

Mice
Zfp148 gt/+ mice 20 and wild-type littermates were backrossed >10 generations and maintained on a pure Apoe -/-C57Bl/6 N genetic background (Taconic, Denmark) and subsequently crossed with Trp53 tm1Tyj/+ (Trp53 +/-) mice (JAX Mice). Polymerase chain reaction primers used for genotyping are described in Online Table I . The mice were housed in individually ventilated cages with 12 hours light cycle and access to food and water ad libitum. All animal experiments were approved by the animal research ethics committee in Gothenburg, Sweden.
Diet
Mice were fed a high-fat (Harlan TD-88137 42% fat 0.2% cholesterol) or a normal chow diet (Harlan 2016 Teklad Global 16% Protein Rodent Diet).
Analysis of Aortas
Whole aortas were dissected, fixed in 4% formaldehyde, pinned out, and stained with Sudan IV as described. 21 Aortic roots were frozen in optimal cutting temperature freezing medium, sectioned and stained with Oil Red O. 22
Immunohistochemistry
The primary antibodies, anti-α-smooth muscle actin (Sigma #F3777; 1:1000) and anti-Mac2 (anti-Mac2-FITC conjugate; Cedarlane; 1:1000), were used for immunohistochemistry and visualized with Vectastain ABS kit alkaline phosphatase (Vector AK-5000) and Fast Red (Vulcan Fast Red Chromogen Kit 2, Biocare Medical). Anti-CD3 (abcam ab5690; 1:1000), anti-cleaved caspase-3 (Cell Signaling Technology, 9961; 1:200), anti-Ki-67 (abcam ab16667; 1:500), and anti-p-p53 (Cell Signaling Technology, 9284; 1:500) were used for immunofluorescence and visualized with the TSA Cyanine 3 System (PerkinElmer) or goat anti-rabbit Cy3. Anti-CD68 (Novocastra Laboratories, Newcastle; 1:500) and anti-Znf148 (HPA001656, atlas antibodies, Sigma Aldrich; 1:25) were used for immunohistochemistry and visualized with Ultra vision LP detection system: HRP polymer/DAB plus Chromogen (TL-015-HD; Thermo scientific). Images were obtained with a Leica Image1 microscope (Leica Microsystems AG), a MIRAX Scan (Carl Zeiss, Germany) or the Metafer Slide Scanning Platform (MetaSystems). Images for quantification were merged with Photoshop using the photomerge function (Adobe) and image analyses were done with BioPix iQ software (version 2.1.8., BioPix).
Blood Analysis
Cholesterol and triglycerides were measured on a Konelab 20 autoanalyzer (Thermo Scientific; Vantaa, Finland). Lipoprotein fractions were determined by size exclusion chromatography using 1 Superdex 200 column (24 mL) and 1 Superose 6HR 10/30 column (24 mL) coupled in series on an ÄKTA Explorer chromatography system (Amersham Pharmacia Biotech, Uppsala, Sweden). Plasma cytokines were analyzed with a SECTOR imager 2400 reader (Meso Scale Discovery, Gaithersburg, MD). Peripheral blood was transferred to EDTA-coated Microvette tubes (Sarstedt) for total white blood cell counts and analyzed on a Hemato analyzer KX21N (Sysmex).
Macrophage Isolation
Peritoneal macrophages were isolated by flushing the peritoneum with PBS and were then cultured overnight as described. 23 Lesional macrophages were isolated as described. 24, 25 Briefly, aortas were perfused with PBS, cut up longitudinally, pinned with intimal area facing upward. A thin layer of digestion mixture containing 450 U/ mL collagenase I, 125 U/mL collagenase XI, 60 U/mL DNase I and 60 U/mL hyaluronidase (Sigma-Aldrich) was applied for 15 minutes in room temperature on top of lesions. After the incubation, lesions were scraped off underlying media with a glass cover slip and further digested for 40 minutes at 37°C to a single-cell suspension with the enzymatic digestion mixture described above.
Real-Time Reverse Transcription Polymerase Chain Reaction
TaqMan assays were performed as described 26 using TaqMan universal polymerase chain reaction mastermix (Applied Biosystems) and the predesigned TaqMan assays (Applied Biosystems) listed in Online Table I .
Isolation and Modification of Triglycerides and Low-Density Lipoprotein Particles
Triglyceride-rich particles were isolated from plasma obtained from Apoe -/mice fed a high-fat diet for 12 weeks as described. Lowdensity lipoprotein (LDL) and acetylated LDL were purchased from Kalen biomedicals.
Minimally oxidized LDL was prepared by incubating LDL at 4°C for 3 months, after which thiobarbituric acid-reactive substances were determined (<3.7 nmol thiobarbituric acid-reactive substance/ mg protein) as described. 27 
Accumulation of Lipids in Macrophages
Peritoneal macrophages were cultured for 24 hours in the presence of triglyceride-rich particles, 50 μg/mL minimally oxidized LDL, or 50 μg/mL acetylated LDL and stained with Oil Red O. Total amount of Oil Red O-stained lipids were quantified from images using the BioPix iQ software (version 2.3.1., BioPix) as described. 28
Bone Marrow Transplantation
Bone marrow cells were harvested from femur and tibia of donor mice. One week before and 2 weeks after transplantation, recipient mice were given acidified water with 100 mg/L neomycin and 10 mg/L polymyxin B sulfate. Eight-week-old recipient mice were irradiated with 9.25GY and reconstituted with 10 7 unfractionated donor cells in 200 μL RPMI-1640 as described. 29 Irradiation efficacy was verified with white blood cell counts 3 days after irradiation. Two weeks after transplantation the mice were switched to a high-fat diet for 12 weeks and analyzed for atherosclerosis at 22 weeks of age. 
Nonstandard Abbreviations and Acronyms
Fluorescence-Activated Cell Sorter Analysis
Peripheral blood, spleen, and bone marrow were isolated from bone marrow-transplanted mice on a high-fat diet at 22 weeks of age or from nontransplanted mice on a chow diet at 46 weeks of age, and single-cell suspensions were prepared in PBS with 2 mmol/L EDTA. Samples were treated with Red Cell Lysis (Sigma) according to the manufacturer's recommendation, to reduce the erythrocyte population. Atherosclerotic lesions were isolated from mice put on high-fat diet for 12 weeks. Isolated cells (5×10 6 cells/sample) were washed once in PBS with 0.1% bovine serum albumin, blocked with Fc-block (CD16/CD32; Becton Dickinson Biosciences) at a 1:100 dilution and incubated on ice in the presence of specific monoclonal antibodies for 20 minutes in the dark. Labeled antibodies against the following cell surface markers were purchased from Becton Dickinson Biosciences; CD4, CD8a, B220, Gr1, CD45, CD11b/Mac1, c-kit, Sca-1, Thy1/ CD90, CD115, Ly6c, F4/80, lineage marker cocktail for bone marrow cells (Lin including B220, CD4, CD8a, Ter119, Gr1, Cd11b/Mac1) and lineage marker cocktail for lesional macrophages (Lin including Thy1/CD90, B220, CD49b, NK1.1, Gr1, Ter119, CD11c). For detection of 5-bromo-2-deoxyuridine (BrdU)-positive cells, BrdU Flow Kit (BD Biosciences) was used according to the manufacturer's instructions in mice pulsed 2 hours with BrdU. 7-Aminoactinomycin D was used as a viability stain. Expression of cell surface markers was detected on a FACSAria or an Accuri C6 flow cytometer (Becton Dickinson Biosciences) and data were analyzed using BD FACS Diva or CFLOW Plus Analysis (Becton Dickinson Biosciences) software.
Western Blotting
Total protein extracts from macrophages were analyzed as before 30 using antibodies recognizing total p53 (fl393, Santa Cruz Biotechnology); phospho-p53 Ser15 (9284, Cell Signaling Technology); γH2AX (05-636, Millipore), and β-tubulin (926-68072, Li-Cor). Secondary antibodies were anti-mouse IRDye 680RD (926-68072, Li-Cor) and antirabbit 680RD (926-68071, Li-Cor). Protein bands were detected on a Li-Cor Odyssey Imager with Odyssey Software (version 3.0, Li-Cor).
Apoptosis
Apoptosis was evaluated with terminal deoxynucleotidyl transferase dUTP nick end labeling using the ApopTag Fluorescence In Situ Apoptosis Detection Kit (Millipore) or with antibodies recognizing cleaved caspase-3 as described before. 30
Carotid Atherosclerotic Plaques
Samples of symptomatic carotid atherosclerotic plaques were obtained from the Göteborg Atheroma Study Group biobank of patients undergoing carotid endarterectomy at the Sahlgrenska University Hospital (Gothenburg, Sweden) 31 The study was approved by the regional ethics committee, and all subjects gave informed consent to participate.
Statistics
Values are mean±SEM. Statistics were performed with 2-tailed Student t test for comparisons between 2 groups: 1-way ANOVA with Tukey's post hoc test for multiple groups and 2-way ANOVA for multiple groups and genotypes. Statistics for plasma cytokines were performed with nonparametric Mann-Whitney test. Differences between groups were considered significant when P<0.05.
Results
To define the importance of Zfp148 in atherogenesis, Zfp148 gt/+ mice were bred onto an Apoe -/genetic background (from here on designated Zfp148 gt/+ ). Attempts to generate Zfp148 gt/gt mice failed, suggesting that the Zfp148 gt/gt genotype is lethal on this background (data not shown). The study was therefore done on Zfp148 gt/+ mice. Zfp148 gt/+ and Zfp148 +/+ littermate controls were fed a high-fat diet from 8 weeks of age and euthanized at 20 weeks of age. En face analysis of Sudan IV-stained aortas showed markedly smaller lesion areas in Zfp148 gt/+ mice compared with Zfp148 +/+ controls ( Figure 1A) . Similarly, lesion areas were smaller on sections from the aortic root of Zfp148 gt/+ mice ( Figure 1B ; Online Figure I ). There was no difference in cellular composition of lesions from Zfp148 gt/+ mice or controls, as judged by staining for biomarkers of smooth muscle cells (α-smooth muscle actin), macrophages (Mac2), or T cells (CD3; Figure 1C -1E).
And there was no difference in necrotic area per lesion area ( Figure 1F ). To test whether the extent and length of hyperlipidemia influence the effect of Zfp148 deficiency, a second cohort of mice was fed a chow diet for 50 weeks. In line with our first experiment, lesion areas were significantly smaller in Zfp148 gt/+ mice compared with Zfp148 +/+ controls (Figure 2A and 2B). We conclude that loss of a single copy of Zfp148 reduces atherogenesis without affecting the cellular composition of the plaques and irrespective of the type of diet. All experiments from hereon were performed on mice fed a highfat diet, unless otherwise indicated. We next investigated the effect of Zfp148 deficiency on systemic inflammation. Quantification of inflammatory markers in plasma at 20 weeks of age showed lower levels of the proinflammatory cytokines interferon-γ and interleukin (IL)-12 and lower levels of the anti-inflammatory cytokine IL-10 in Zfp148 gt/+ mice compared with controls ( Figure 3A) . To investigate the possibility that Zfp148 is directly involved in the regulation of inflammatory cytokines, peritoneal macrophages from Zfp148 gt/+ mice and controls were investigated for cytokine expression after stimulation with triglyceriderich lipoproteins. There were no differences in mRNA levels for chemokine (C-X-C motif) ligand 1, chemokine (C-X-C motif) ligand 2, IL-10, IL-1b, IL-6, or tumor necrosis factorα between Zfp148 gt/+ macrophages and Zfp148 +/+ controls, whereas the levels of chemokine (C-X-C motif) ligand 10 were increased (P<0.05) and the levels of chemokine (C-C motif) ligand 2 were decreased (P<0.05) ( Figure 3B ). Although decreased chemokine (C-C motif) ligand 2 expression could reduce atherosclerosis, there was no difference in protein concentration of chemokine (C-C motif) ligand 2, or any of the other tested cytokines, between media conditioned by Zfp148 gt/+ macrophages and controls after stimulation with triglyceride-rich lipoproteins, minimally modified LDL, or acetylated LDL (Online Figure II) . Thus, smaller lesion areas in Zfp148 gt/+ mice are not likely caused by mitigated inflammation.
Hyperlipidemia and the accumulation of cholesterol in macrophages play a central role in the pathogenesis of atherosclerosis. We therefore investigated our mice for signs of disturbed lipid metabolism. Body weight, plasma triglycerides, and plasma cholesterol levels were similar in Zfp148 gt/+ mice compared with controls (Online Figure IIIA and IIIB) . Furthermore, there was no difference in plasma lipoprotein fractions of very low-density lipoprotein, LDL, intermediate-density lipoprotein, or high-density lipoprotein between Zfp148 gt/+ mice and Zfp148 +/+ controls, as judged by size exclusion chromatography (Online Figure IIIC) . To determine whether the smaller lesion area in Zfp148 gt/+ mice could be explained by reduced accumulation of lipids in macrophages, we October 10, 2014 measured Oil red O-stained lipids in peritoneal macrophages after 24-hour incubation with triglyceride-rich lipoproteins, minimally modified LDL, or acetylated LDL. There was no difference in the amount of stained lipids between cells from Zfp148 gt/+ mice and controls (Online Figure IIID-IIIF) . There was further no difference in mRNA levels for genes coupled to lipid uptake or export (Online Figure IIIG) . Thus, Zfp148 gt/+ mice exhibited reduced arthrosclerosis without evidence for effects on lipid metabolism.
To define the effector cell that suppresses atherosclerosis in Zfp148 gt/+ mice, we performed bone marrow transplantations to lethally irradiated recipients at 8 weeks of age. After 2-week recovery, the mice were put on a high-fat diet for 12 weeks. Zfp148 +/+ mice and Zfp148 gt/+ mice that received Zfp148 gt/+ bone marrow exhibited markedly smaller lesion areas compared with mice transplanted with Zfp148 +/+ bone marrow ( Figure 4A ). In contrast, there was no difference between Zfp148 gt/+ mice and Zfp148 +/+ mice that were both transplanted with Zfp148 +/+ bone marrow. Thus, the effector cell is of hematopoietic origin.
T cells, B cells, and monocytes are important for the formation of atherosclerosis. Because Zfp148 has been implicated in hematopoiesis, development of those lineages could be negatively affected in Zfp148 gt/+ mice. [32] [33] [34] [35] To test this possibility, we performed fluorescence-activated cell sorter analysis of peripheral blood, bone marrow, and spleens from Zfp148 +/+ mice transplanted with Zfp148 gt/+ or Zfp148 +/+ bone marrow and from nontransplanted Zfp148 gt/+ mice and controls. There was no difference in circulating T cells, B cells, neutrophils, monocytes, or total white blood cells between mice transplanted with Zfp148 gt/+ or Zfp148 +/+ bone marrow or between Zfp148 gt/+ mice and controls ( Figure 4B and 4F ; Online Figures IV-VI) . Notably, levels of Ly6C low monocytes were lower in spleens from Zfp148 +/+ mice transplanted with Zfp148 gt/+ bone marrow compared with controls (Online Figure IVB) . However, this difference was not recapitulated in spleens from nontransplanted Zfp148 gt/+ mice and controls (Online Figure V) . And there was no difference in bone marrow progenitor cells (lineage-negative or Lin -Sca1 + cKit + ; Online Figures IV and V) . The results are consistent with our earlier data showing that Zfp148 is dispensable for hematopoietic development in mice. 36 In conclusion, reduced atherosclerosis in Zfp148 gt/+ mice is not caused by intrinsic defects in hematopoietic development.
Zfp148 interacts physically with the check point protein p53, 19 and inactivation of both copies of Zfp148 leads to p53dependent cell proliferation arrest and lethality in new-born mice. 19, 20 We therefore hypothesized that Zfp148 haploinsufficiency could reduce atherosclerosis by unleashing p53 activity. Consistent with this idea, peritoneal macrophages from Zfp148 gt/+ mice contained more phosphorylated p53 after stimulation with minimally modified LDL, compared with controls ( Figure 5A ). There was, however, no difference in total amount of p53, suggesting that Zfp148 deficiency accentuates p53 activation without affecting p53 stabilization. Moreover, levels of γH2AX were similar in Zfp148 gt/+ macrophages and controls arguing against differences in DNA damage. To assess whether Zfp148 deficiency affects p53 activity in vivo, we measured phosphorylated p53 at the level of the aortic root. Atherosclerotic plaques from Zfp148 gt/+ mice contained more cells expressing phosphorylated p53 compared with controls, in line with the in vitro data ( Figure 5B ).
We next investigated whether cell proliferation or apoptosis was affected. Aortic roots from Zfp148 gt/+ mice contained fewer Ki67-positive cells per lesion area compared with controls ( Figure 5C ). There was no difference in Ki67positive cells in the aortic media/adventitia (Online Figure  VIIA) , indicating that cell proliferation is reduced in lesions, but not in normal arterial walls. Moreover, the number of apoptotic cells per lesion area was markedly increased in Zfp148 gt/+ mice compared with controls ( Figure 5D ; Online Figure VIIB) .
To define the identity of the proliferating cells, atherosclerotic lesions from the whole aorta were isolated after a 2-hour BrdU pulse and analyzed by fluorescence-activated cell sorter. Lesions from Zfp148 gt/+ mice showed a 50% reduction in BrdU-positive Lin -CD11b + F4/80 + macrophages compared with controls ( Figure 5E ). Because monocytes that proliferate in the bone marrow do not enter the circulation during a 2-hour BrdU pulse, 24 the data indicate proliferation of tissue macrophages in lesions. There was no difference in the percentage of BrdU-positive CD45 + Thy1 + cells, which mainly consists of T cells, suggesting that the effect is selective for macrophages (Online Figure VIIC) .
To assess whether p53 is required for attenuating atherosclerosis in Zfp148 gt/+ mice, we crossed the Zfp148 gt/+ mice onto a Trp53 +/genetic background. Zfp148 gt/+ mice developed less atherosclerosis compared with Zfp148 +/+ controls on Trp53 +/+ background ( Figure 6A and 6B) , thus reproducing earlier data. Strikingly, there was no difference in lesion area between Zfp148 gt/+ and Zfp148 +/+ mice on Trp53 +/background. Similarly, there was no difference in expression of phosphorylated p53 or the proliferation marker Ki67 on Trp53 +/background ( Figure 6C and 6D) . In contrast, lesions from Zfp148 gt/+ mice contained more apoptotic cells compared with controls, on both Trp53 +/+ and Trp53 +/backgrounds ( Figure 6E ; Online Figure VIII) . Thus, apoptosis plays a minor role for reduced atherogenesis in Zfp148 gt/+ mice. We conclude that Zfp148 deficiency confers protection against atherosclerosis by activating p53, thus reducing proliferation of lesional macrophages.
To assess whether Zfp148 could be of significance in human atherosclerosis, expression of Znf148, the human homologue of Zfp148, was evaluated in atherosclerotic plaques removed by endarterectomy from the carotid arteries in 12 patients with minor stroke or transient ischemic attack. 31 Antibodies recognizing Znf148 consistently showed strong nuclear staining in areas that were rich in macrophages (Online Figure IXA and IXB). Thus, Znf148 is expressed in human atherosclerotic plaques opening up for the possibility that the mechanism we outline is clinically relevant.
Discussion
Our results demonstrate that Zfp148 deficiency reduces atherosclerosis in the Apoe -/model without affecting lipid metabolism. We further show that the effector cell is of hematopoietic origin and that Zfp148 deficiency confers protection against atherosclerosis by increasing p53 activation, thus reducing proliferation of lesional macrophages. This is the first report that associates Zfp148 with atherosclerosis or cardiovascular disease. Importantly, we recorded reduced plaque burden in Zfp148 gt/+ mice compared with controls in 4 independent experiments making this a robust observation. Notably, and for reasons we do not know, the effect was greater in the whole aorta compared with the aortic root. The data did not reveal any differences in lipid metabolism between Zfp148 gt/+ mice or controls. Similarly, there was no general reduction in macrophage expression of inflammatory cytokines or levels of circulating T cells, B cells, or monocytes between Zfp148 gt/+ mice and controls. Thus, our results suggest that Zfp148 deficiency affects atherosclerosis independently of lipid metabolism or inflammation.
One plausible mechanism behind the reduced atherosclerosis in Zfp148-deficient mice is that p53 activation attenuates proliferation of macrophages in atherosclerotic plaques. This proposal is supported by 4 lines of evidence. First, the bone marrow transplantation showed that the effector cell is of hematopoietic origin. Second, peritoneal macrophages and atherosclerotic lesions from Zfp148 gt/+ mice showed increased levels of phosphorylated p53 compared with controls. Third, there were fewer proliferating macrophages in atherosclerotic lesions from Zfp148 gt/+ mice compared with controls. And finally, deletion of 1 copy of Trp53 abolished the effects of Zfp148 deficiency on (1) atherosclerosis development, (2) p53 activation, and (3) cell proliferation. The lack of effect in Trp53 +/mice is not proof that Zfp148 works through this mechanism, as the atheroma is complex and multiple pathways influence its progression in hierarchical but not necessarily interdependent systems. However, the genetic interaction between Zfp148 and Trp53 strongly supports a causal relationship.
Compelling evidence shows that inactivation of p53 accelerates atherosclerosis development in mice, but the mechanism downstream of p53 is not well understood. Although there is a consensus on the hematopoietic origin of the effector cell, conflicting data exist on whether inactivation of p53 increases lesional cell proliferation, 7,10 decreases apoptosis, 9, 37 or both. 8 Our results show that proliferation of lesional macrophages is critical for atherosclerosis development in Apoe -/mice, and that p53 controls the proliferation rate.
Recent findings suggest that local proliferation of macrophages during inflammation is more important than previously thought. 38, 39 In the Apoe -/model, macrophage proliferation, but not recruitment of monocytes from the blood, is critical for the accumulation of lesional macrophages. 24 Proliferating macrophages/monocytes are consistently observed within human primary atherosclerotic plaques at proliferation rates that are similar to those observed in Apoe -/mice. [40] [41] [42] [43] Thus, drugs targeting cell proliferation may confer protection against atherosclerosis.
Apoptosis have pleiotropic effects on atherosclerosis. In early stages, it limits accumulation of macrophages and slows progression of the disease. 44, 45 But it may also cause endothelial dysfunction that accelerates the disease. [46] [47] [48] In advanced lesions, apoptosis of macrophages reduces the capacity for efferocytosis, the removal of dead cells, and thus promotes necrotic core formation and plaque instability. 44, 45 Zfp148 deficiency increased apoptosis in lesions on the Trp53 +/genetic background without affecting atherosclerosis development, in potential conflict with the literature. However, without determining the identity of the apoptotic cells in the Zfp148 gt/+ lesions, data cannot be readily compared. And we did not investigate the mice for effects on efferocytosis or plaque instability.
The renewed interest in drugs targeting cell proliferation brings back the question whether increased p53 activation would reduce atherosclerosis development. Our results strongly support this notion. However, earlier attempts to validate the concept have yielded negative or inconclusive results. 49, 50 Increasing the p53 gene dosage had, for example, no effect on atherosclerosis development. 49 Our findings suggest that endogenous Zfp148 may constitute a barrier toward genetic or therapeutic activation of p53 in atherosclerotic plaques. Such interrelation, if verified, raises the possibility that therapeutic targeting of Zfp148 could reduce atherosclerosis by unleashing p53 activity. Moreover, targeting Zfp148 may circumvent some of the anticipated adverse effects of elevated p53 activity. Activation of p53 in the endothelium, for example, leads to endothelial dysfunction and atherosclerosis, [46] [47] [48] and global activation of p53 is lethal as shown by knockouts of the p53inhibitor Mdm2. 51, 52 Deletion of 1 copy of Zfp148 does not seem to trigger these responses. 
